Senti Biosciences Holdings is a clinical-stage biopharmaceutical company in South San Francisco, California, traded on Nasdaq as SNTI, that engineers synthetic biology into cell and gene therapies. Its original Gene Circuit platform builds proprietary DNA logic into therapeutic cells so they sense their environment, compute a decision, and kill cancer cells while sparing healthy tissue, applied in both NK and T cells. In July 2026 the company announced a strategic transaction transferring its gene-circuit-enabled pipeline, including the lead allogeneic NK cell therapy SENTI-202 for acute myeloid leukemia, to a newly formed private company controlled by its largest investor Celadon, with up to $60 million in milestone payments flowing back to Senti stockholders. Senti is now refocused on its earlier-stage Regulator Dial platform for controllable genetic medicines. It was co-founded in 2016 and is led by CEO Timothy Lu, M.D., Ph.D., a former tenured MIT faculty member in biological and electrical engineering.